Publications by authors named "I B Malone"
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length. Somatic CAG expansion occurs throughout life and understanding the impact of somatic expansion on neurodegeneration is key to developing therapeutic targets. In 57 HD gene expanded (HDGE) individuals, ~23 years before their predicted clinical motor diagnosis, no significant decline in clinical, cognitive or neuropsychiatric function was observed over 4.
View Article and Find Full Text PDFIntroduction: Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD. Autosomal dominant AD (ADAD) provides a unique opportunity to test therapies in presymptomatic individuals.
Methods: Using data from the Dominantly Inherited Alzheimer Network (DIAN), sample sizes for clinical trials were estimated for various cognitive, imaging, and CSF outcomes.
Article Synopsis
- Accelerated long-term forgetting (ALF) describes a situation where information is remembered well in the short term but forgotten quickly over longer periods, and it could be an early sign of cognitive decline, possibly related to Alzheimer's disease.
- In a study involving 429 participants aged about 73, researchers assessed ALF using visual and verbal memory tests and looked at the impact of brain pathology on memory retention and forgetting.
- Results showed that people with amyloid plaques (linked to Alzheimer's) forgot details of a complex figure more quickly than those without, and overall retention was higher for the 'outline' of the figure compared to 'detail' items.
Article Synopsis
- * Three distinct subtypes were found: one with early logical memory changes progressing to tau and white matter issues, another showing early white matter changes with older age and hypertension, and a third resembling typical Alzheimer's disease with early tau signals.
- * The findings suggest that the diversity in these individuals is influenced by co-existing conditions, particularly vascular diseases, indicating that understanding these variations is crucial for better grasping Alzheimer’s disease progression.
Introduction: Recent technological advances have increased the risk that de-identified brain images could be re-identified from face imagery. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a leading source of publicly available de-identified brain imaging, who quickly acted to protect participants' privacy.
Methods: An independent expert committee evaluated 11 face-deidentification ("de-facing") methods and selected four for formal testing.